Page 267 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 267
P0846 EVALUATION OF ADHERENCE TO TELAPREVIR (TVR) AND ePOSTERS
P0847 BOCEPREVIR (BOC) USING DIFFERENT THRESHOLDS
Elena González-Colominas*, Teresa Broquetas, Alexandra Retamero,
P0848 Montserrat García-Retortillo, Nuria Cañete, Marc Puigvehí,
Rosa Pellicer, Dolors Giménez, Beatriz Cabrero, Felipe Bory,
P0849 Esther Salas, Ricard Solà, José A. Carrión, Spain
P0850
MALACHITE-II: PHASE 3B TRIAL OF OMBITASVIR/
PARITAPREVIR/R AND DASABUVIR + RIBAVIRIN OR
TELAPREVIR + PEGINTERFERON/RIBAVIRIN IN
PEGINTERFERON/RIBAVIRIN TREATMENT-EXPERIENCED
ADULTS WITH HCV GENOTYPE 1
Gregory Dore*, Brygida Knysz,Yan Luo, Ewa Janczewska,
Adrian Streinu-Cercel, Florin A. Caruntu, Adriana Motoc,
Włodzimierz Mazur, David Shaw, Istvan Tornai, Joseph Sasadeusz,
Richard Skoien, Danielle Sullivan, Xuan Liu, Thomas Podsadecki,
Australia
EFFICACY OF RESPONSE-GUIDED PEGYLATED
INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO
INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE
ACTIVATE STUDY
Jason Grebely*, Olav Dalgard, Brian Conway, Graham Foster,
Philip Bruggmann, Markus Backmund, Geert Robaeys, Tracy Swan,
Behzad Hajarizadeh, Janaki Amin, Phillipa Marks, Sophie Quiene,
Martin Weltman, David Shaw, Adrian Dunlop, Margaret Hellard,
Julie Bruneau, Stefan Bourgeois, Christine Thurnheer, Gregory J. Dore,
Australia
REAL-WORLD EFFECTIVENESS OF SOFOSBUVIR (SOF),
TELAPREVIR, AND BOCEPREVIR (T, B) BASED THERAPY
FOR HEPATITIS C VIRUS (HCV): AN ANALYSIS IN A LARGE
INTEGRATED HEALTH CARE SYSTEM
Jennifer B. Lai*, David J. Witt, Maxwell A. Witt, The United States
PERCENT OF SUBJECTS EXPERIENCING LIVER
MORBIDITY OVER A LIFETIME HORIZON WITH ABBVIE
3D (ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR)
VERSUS NO TREATMENT
Scott J. Johnson, Hélène Parisé, Suchin Virabhak, Derek A. Misurski,
Timothy R. Juday, Jennifer C. Samp*, Steve E. Marx, Sammy Saab,
The United States
Vienna, Austria • April 22–26, 2015 267
P0847 BOCEPREVIR (BOC) USING DIFFERENT THRESHOLDS
Elena González-Colominas*, Teresa Broquetas, Alexandra Retamero,
P0848 Montserrat García-Retortillo, Nuria Cañete, Marc Puigvehí,
Rosa Pellicer, Dolors Giménez, Beatriz Cabrero, Felipe Bory,
P0849 Esther Salas, Ricard Solà, José A. Carrión, Spain
P0850
MALACHITE-II: PHASE 3B TRIAL OF OMBITASVIR/
PARITAPREVIR/R AND DASABUVIR + RIBAVIRIN OR
TELAPREVIR + PEGINTERFERON/RIBAVIRIN IN
PEGINTERFERON/RIBAVIRIN TREATMENT-EXPERIENCED
ADULTS WITH HCV GENOTYPE 1
Gregory Dore*, Brygida Knysz,Yan Luo, Ewa Janczewska,
Adrian Streinu-Cercel, Florin A. Caruntu, Adriana Motoc,
Włodzimierz Mazur, David Shaw, Istvan Tornai, Joseph Sasadeusz,
Richard Skoien, Danielle Sullivan, Xuan Liu, Thomas Podsadecki,
Australia
EFFICACY OF RESPONSE-GUIDED PEGYLATED
INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO
INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE
ACTIVATE STUDY
Jason Grebely*, Olav Dalgard, Brian Conway, Graham Foster,
Philip Bruggmann, Markus Backmund, Geert Robaeys, Tracy Swan,
Behzad Hajarizadeh, Janaki Amin, Phillipa Marks, Sophie Quiene,
Martin Weltman, David Shaw, Adrian Dunlop, Margaret Hellard,
Julie Bruneau, Stefan Bourgeois, Christine Thurnheer, Gregory J. Dore,
Australia
REAL-WORLD EFFECTIVENESS OF SOFOSBUVIR (SOF),
TELAPREVIR, AND BOCEPREVIR (T, B) BASED THERAPY
FOR HEPATITIS C VIRUS (HCV): AN ANALYSIS IN A LARGE
INTEGRATED HEALTH CARE SYSTEM
Jennifer B. Lai*, David J. Witt, Maxwell A. Witt, The United States
PERCENT OF SUBJECTS EXPERIENCING LIVER
MORBIDITY OVER A LIFETIME HORIZON WITH ABBVIE
3D (ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR)
VERSUS NO TREATMENT
Scott J. Johnson, Hélène Parisé, Suchin Virabhak, Derek A. Misurski,
Timothy R. Juday, Jennifer C. Samp*, Steve E. Marx, Sammy Saab,
The United States
Vienna, Austria • April 22–26, 2015 267
